Combination Immunotherapy in Rare Cancers Under InvesTigation
A phase 2 trial of nivolumab and ipilimumab in gallbladder cancer and other biliary tract cancers, run by Olivia Newton-John Cancer Research Institute, active and no longer recruiting.
Overview
Combination Immunotherapy in Rare Cancers Under InvesTigation is a phase 2 interventional study registered as NCT04969887 by Olivia Newton-John Cancer Research Institute, with a registry enrolment figure of 240 participants, started 2021-08-03 and due to reach its primary completion in 2025-03-01. Interventions recorded: Ipilimumab, Nivolumab. Conditions listed: Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm, MSI-H Solid Malignant Tumor. Gallbladder cancer is named in the registry entry: "* a) Histologically confirmed Neuroendocrine cancers: Atypical bronchial carcinoid, neuroendocrine carcinoma and Grade 3 NETs independent of primary site (SCLC excluded); Biliary Tract Cancers: Intrahepatic cholangiocarc". Sites: Australia, New Zealand. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAgnostic Therapy in Rare Solid Tumors
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Nivolumab, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
- TrialStudy on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
- TrialImmunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
- TrialKN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
- TrialThe Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
- TrialBecotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase II
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
- TrialChemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-deep-dive.
- TrialA Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-deep-dive.